Research on Treatments for Alzheimer’s Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Source Cluster: JCN Newswire Source Node: 1966335Time Stamp: Apr 17, 2024
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA Source Cluster: JCN Newswire Source Node: 1961159Time Stamp: Mar 31, 2024
Lifenet and Eisai Co-Develop Dementia Insurance “be” Source Cluster: JCN Newswire Source Node: 1957889Time Stamp: Mar 21, 2024
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients Source Cluster: JCN Newswire Source Node: 1954073Time Stamp: Mar 6, 2024
“LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20 Source Cluster: JCN Newswire Source Node: 1925109Time Stamp: Dec 14, 2023
Tokio Marine Nichido and Eisai Co-Develop Industry’s First “Dementia Care Support Insurance” Source Cluster: JCN Newswire Source Node: 1895560Time Stamp: Sep 28, 2023
“LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan Source Cluster: JCN Newswire Source Node: 1893980Time Stamp: Sep 25, 2023
Study found link between Periodontitis and Alzheimer’s Disease Source Cluster: Tech Explorirst Source Node: 1588481Time Stamp: Jul 22, 2022